Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2006-04-11
2006-04-11
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S230100, C435S235100, C435S236000
Reexamination Certificate
active
07025968
ABSTRACT:
The invention provides methods and compositions for inhibiting CMV infection and dissemination in an animal, as well as in vitro and in vivo assay systems for identifying such compositions.
REFERENCES:
patent: 3379729 (1968-04-01), Protiva et al.
patent: 4243805 (1981-01-01), Protiva et al.
patent: 5529771 (1996-06-01), Hooks et al.
patent: 5652133 (1997-07-01), Murphy
patent: 5665362 (1997-09-01), Inglis et al.
patent: 5720957 (1998-02-01), Jones et al.
patent: 5753476 (1998-05-01), Jones et al.
patent: 5756264 (1998-05-01), Schwartz et al.
patent: 5763217 (1998-06-01), Cynader et al.
patent: 5824318 (1998-10-01), Mohr et al.
patent: 5843458 (1998-12-01), Jones
patent: 5846806 (1998-12-01), Jones et al.
patent: 5866136 (1999-02-01), Ramshaw et al.
patent: 5877004 (1999-03-01), Jones et al.
patent: 5908780 (1999-06-01), Jones
patent: 5939320 (1999-08-01), Littman et al.
patent: 5948775 (1999-09-01), Koko et al.
patent: 5965697 (1999-10-01), Czaplewski et al.
patent: 5998160 (1999-12-01), Berens
patent: 6028169 (2000-02-01), Kreider et al.
patent: 6031080 (2000-02-01), Williams et al.
patent: 6034102 (2000-03-01), Aiello
patent: 6051375 (2000-04-01), Rose et al.
patent: 6051428 (2000-04-01), Fong et al.
patent: 6150132 (2000-11-01), Wells et al.
patent: 6420121 (2002-07-01), Nelson et al.
patent: 2002/0127544 (2002-09-01), Schall et al.
patent: 0 277 773 (1988-08-01), None
patent: WO 94/11504 (1994-05-01), None
patent: WO 96/23068 (1996-08-01), None
patent: WO 98/02151 (1998-01-01), None
patent: WO 98/11073 (1998-03-01), None
patent: WO 99/00510 (1999-01-01), None
patent: WO 99/09178 (1999-02-01), None
patent: WO 99/27122 (1999-06-01), None
patent: WO 99/36562 (1999-07-01), None
patent: WO 99/36568 (1999-07-01), None
patent: WO 99/61472 (1999-12-01), None
patent: WO 00/00491 (2000-01-01), None
patent: WO 00/06203 (2000-02-01), None
patent: WO 00/11950 (2000-03-01), None
patent: WO 00/34494 (2000-06-01), None
patent: WO 02/17900 (2002-03-01), None
patent: WO 02/17969 (2002-03-01), None
patent: WO 02/18954 (2002-03-01), None
patent: WO 02/062296 (2002-08-01), None
Krause et al (Infectious Disease Clinics of North America 13(1):61-81, Mar. 1999).
Beisser et al (Journal of Virology 72(3):2352-2363, 1998).
Beisser et al (Journal of Virology 73(9):7218-7230, 1999).
Hwang et al (Microbiology and Immunology 43(3):307-310, 1999).
Kropff et al (Journal of General Virology 78:2009-2013, 1997).
Kravitsz et al (Journal of General Virology 78:1999-2007, 1997).
Beers, M. et al.The Merck Manual of Diagnosis and Therapy, 17th Ed., 1999, pp. 1294-1296, Published by Merck Research Laboratories.
Hardman, J. et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., 1996, p. 51, 57-58, McGraw-Hill, printed in the U.S.A.
Horuk, R. “Molecular properties of the chemokine receptor family”,Trends Pharm. Sci., vol. 15, (1994), pp. 159-165.
Schall, T.J. et al., “Chemokines, leukocyte trafficking, and inflammation”, Curr. Opin. Immunol., vol. 6, (1994), pp. 865-873.
Sindelar, K et al. “Neurotropic and psychotropic agents”, Res. Inst. Pharm. Biochem., 1976, pp. 910-922, vol. 41, No. 3,Abstract only.
Zlotnik et al. “Recent Advances in Chemokines and Chemokine Receptors” Critical Reviews in Immunology, 1999, pp. 1-47, vol. 19.
Branch, Andrea D.; A good antisense molecule is hard to find;TIBS 23; Feb. 1998; pp. 45-50.
Crooke, Stanley T. et al.;Antisense Research and Applications; Basic Principles of Antisense Therapeutics; chapters 1-3; pp. 1-53.
Crystal, Ronald G.; Transfer of Genes to Humans: Early Lessons and Obstacles to Success;Science; pp. 404-410; Oct. 20, 1995; vol. 270.
Francken, Bart J.B., et al.; Human 5-Hydroxytryptamine5AReceptors Activate Coexpressed G1and GoProteins inSpodoptera frugiperda9 Cells;Molecular Pharmacology; pp. 1034-1044; May 2000; vol. 57, No. 5.
Ha, Hunjoo, et al.; Atherogenic lipoproteins enhance mesangial cell expression of platelet-derived growth factor: Role of protein tyrosine kinase and cyclic AMP-dependent protein kinase A;J Lab Clin Med; pp. 456-465; May 1998.
Koyama, Noriyuki, et al.; Heparan Sulfate Proteoglycans Mediate a Potent Inhibitor Signal for Migration of Vascular Smooth Muscle Cells;Circulation Research; pp. 305-313; Aug. 10, 1998; vol. 83, No. 3.
Kung, H.F., et al.; Dopamine D-2 Receptor Imaging Radiopharmaceuticals: Synthesis, Radiolabeling, and in Vitro Binding of (R)-(+)- and (S)-(−)-3-Iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl) methyl] benzamide:Journal of Medical Chemistry; pp. 1039-1042; 1998; vol. 31, No. 5.
Manning, William C., et al.; Use of a recombinant murine cytomegalovirus expressing vesicular stomatitis virus G protein to pseudotype retroviral vectors;Journal of Virological Methods; 1998; pp. 31-39; vol. 73.
McNall, Steven J., et al.; Novel Serotonin Receptors in Fasciola. Characterization by Studies on Adenylate Cyclase Activation and [3H]LSD Binding;Biochemical Pharmacoogy.; pp. 2789-2797; 1984; vol. 33, No. 17.
Padia, J.K., et al.; Design and Synthesis of Novel Nonpepetide CCK-B Receptor Antagonists;Bioorganic&Medicinal Chemistry Letters; pp. 805-810; 1997; vol. 7, No. 7.
Padia, J.K., et al.; Novel Nonpeptide CCK-B Antagonists: Design and Development of Quinazolinone Derivatives as Potent, Selective, and Orally Active CCK-B Antogonists;Journal of Medicinal Chemistry, pp. 1042-1049; 1998; vol. 41, No. 7.
Palù, Giorgio, et al.; In pursuit of new developments for gene therapy of human diseases;Journal of Biotechnology, pp. 1-13; 1999; vol. 68.
Schall, T.J., et al.; Biology of the Rantes/SIS Cytokine Family;Cytokine; pp. 165-183; May 1991; vol. 3, No. 3
Schofield, J.P., et al.; Non-viral approaches to gene therapy;British Medical Bulletin; pp. 56-71; 1995; vol. 51, No. 1.
Verma, Inder M., et al.; Gene therapy—promises, problems and prospects;Nature; pp. 239-242; Sep. 18, 1997; vol. 389.
Wang, T.S., et al; A Simple Method of Preparation for [123I]-(S)-(−)-IBZM;Applied Radiation and Isotopes; pp. 389-372; 1998; vol. 49, No. 4.
Beisser, Patrick S., et al.; The R33 G Protein-Coupled Receptor Gene of Rat Cytomegalovirus Plays an Essential Role in the Pathogenesis of Viral Infection;Journal of Virology; Mar. 1998; pp. 2352-2363; vol. 72, No. 3.
Beisser, Partick S., et al.; Delection of the R78 G Protein-Coupled Receptor Gene from Rat Cytomegalovirus Results in an Attenuated, Syncytium-Inducing Mutant Strain;Journal of Virology; Sep. 1999; pp. 7218-7230; vol. 73, No. 9.
Beisser, P.R., et al.; Viral Chemokine Receptors and Chemokines in Human Cytomegalovirus Trafficking and Interaction with the Immune System;Current Topics in Microbiology and Immunology; 2002; pp. 203-234; vol. 269; Springer; Berlin, DE; XP008009472.
Billstrom, Marcella A. et al.; Intracellular Signaling by the Chemokine Receptor US28 during Human Cytomegalovirus Infection;Journal of Virology, Jul. 1998; pp. 5535-5544; vol. 72, No. 7.
Bodaghi, Bahram, et al.; Chemokine Sequestration by Viral Chemoreceptors as a Novel Viral Escape Strategy: Withdrawal of Chemokines from the Environment of Cytomegalovirus-Infected Cells;J. Exp. Med.; Sep. 7, 1998; pp. 855-866; vol. 188, No. 5.
Borst, M.E., et al.; Development of a cytomegalovirus vector for somatic gene therapy;Bone Marrow Transplantation; 2000; pp. S80-S82; Supp. 2.
Cha, Tai-An, et al.; Human Cytomegalovirus Clinical Isolates Carry at Least 19 Genes Not Found in Laboratory Strains;Journal of Virology; Jan. 1996; pp. 78-83; vol. 70, No. 1.
Chee, M.S., et al.; Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169;Current Topics in Microbiology and Immunology; 1990; pp. 126-169; vol. 154.
Chee, M.S., et al.; Human cytomegalovirus encodes three G protein-coupled receptor homologues;Nature; Apr. 19, 1990; pp. 774-777; vol. 344.
Craigen, J.L., et al.; Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration;Immunology; 1997; pp. 138-145; vol. 92.
Davis-Poynter, Nicholas J., et al.; Master of deception: A review of herp
Penfold Mark E. T.
Schall Thomas J.
ChemoCentryx, Inc.
Mosher Mary E.
LandOfFree
CMV vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CMV vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CMV vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3567818